Stock Report: Sinovac Biotech Ltd. (SVA) Report Updated: May 20, 2013 | Print This Page

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. It offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination of hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the influenza A H1N1 virus. The company's pipeline vaccine candidates include a split viron vaccine, which completed Phase II clinical trials for the H5N1 influenza virus; and a SARS vaccine, which completed Phase I clinical trials for the SARS virus. In addition, its pipeline vaccine candidates that completed the pre-clinical trials comprise human vaccines for EV71, pneumococcal conjugate, haemophilus influenzae type b, meningitis, Japanese encephalitis, chickenpox, mumps, and rubella diseases, as well as rabies vaccine for humans and animals. The company markets and sells its vaccine products directly to the provincial and municipal disease control and prevention centers. It has a patent license agreement with the National Institutes of Health; distribution agreements with LG Life Sciences, Ltd. and Glovax C.V.; and a pandemic influenza vaccine co-development agreement with the China Center for Disease Control and Prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.